company background image
MNPR logo

Monopar Therapeutics NasdaqCM:MNPR Stock Report

Last Price

US$24.00

Market Cap

US$136.3m

7D

-10.1%

1Y

1,105.4%

Updated

23 Dec, 2024

Data

Company Financials +

Monopar Therapeutics Inc.

NasdaqCM:MNPR Stock Report

Market Cap: US$136.3m

MNPR Stock Overview

A clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. More details

MNPR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Monopar Therapeutics Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Monopar Therapeutics
Historical stock prices
Current Share PriceUS$24.00
52 Week HighUS$38.50
52 Week LowUS$1.55
Beta1.24
1 Month Change19.40%
3 Month Change444.22%
1 Year Change1,105.42%
3 Year Change51.42%
5 Year Change-74.12%
Change since IPO-81.89%

Recent News & Updates

Recent updates

We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Aug 13
We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?

Feb 27
Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?

Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely?

Mar 02
Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely?

We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Nov 16
We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Monopar stock soars 19% as enrollment finishes in phase 2 part of oral mucositis study of Validive

Oct 05

We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate

Jul 30
We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate

Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans

Mar 28
Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash Wisely

Jul 15
We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation

Mar 26
Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation

Monopar nabs U.S. patent covering camsirubicin

Dec 22

Monopar Therapeutics selects targeted immuno-therapeutic candidate for COVID-19

Dec 10

Monopar launches validive mid-stage study in chemo-induced oral mucositis

Dec 08

Monopar Therapeutics EPS beats by $0.02

Nov 12

Shareholder Returns

MNPRUS BiotechsUS Market
7D-10.1%-3.3%-2.2%
1Y1,105.4%-1.9%23.9%

Return vs Industry: MNPR exceeded the US Biotechs industry which returned -2.6% over the past year.

Return vs Market: MNPR exceeded the US Market which returned 23.4% over the past year.

Price Volatility

Is MNPR's price volatile compared to industry and market?
MNPR volatility
MNPR Average Weekly Movement171.9%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: MNPR's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: MNPR's weekly volatility has increased from 90% to 171% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201410Chandler Robinsonwww.monopartx.com

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers.

Monopar Therapeutics Inc. Fundamentals Summary

How do Monopar Therapeutics's earnings and revenue compare to its market cap?
MNPR fundamental statistics
Market capUS$136.27m
Earnings (TTM)-US$6.47m
Revenue (TTM)n/a

0.0x

P/S Ratio

-19.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MNPR income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$6.47m
Earnings-US$6.47m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.23
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did MNPR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 23:03
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Monopar Therapeutics Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian Kemp DolliverBrookline Capital Markets
Kumaraguru RajaBrookline Capital Markets
Sean LeeH.C. Wainwright & Co.